Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Ovarian Epithelial 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Cytarabine 4Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Doxorubicin 3venetoclax 2navitoclax 2merphos 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Pentetic Acid 2Mycophenolic Acid 2Filgrastim 2Etoposide 2Daunorubicin 2Biopsy 2Asparaginase 2sargramostim 1romidepsin 1prednylidene 1pegaspargase 1nelarabine 1lentiviral minigene vaccine of COVID-19 coronavirus 1hydrocortisone hemisuccinate 1ethanolamine oleate 1duvelisib 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × romidepsin × Clear all
NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡